In this regard, others have recently postulated that the heterogeneous phenotype mixture of antigen-specific CD8+ T cells might be a better predictor for the treatment efficacy of cancer vaccines, but that the exact composition might differ between tumor settings [8,33]. This evidence concerns the gene CD8A and cancer.